nVerses Capital’s Compass Therapeutics CMPX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-23,330
Closed -$51.1K – 61
2026
Q2
$51.1K Buy
+23,330
New +$68.9K 0.08% 276

Other funds holding CMPX

nVerses Capital's CMPX Position: Q3 2026 in Review

nVerses Capital sold out of Compass Therapeutics (CMPX) in Q3 2026, closing a stake of 23,330 shares — an estimated $51.1K sold.

nVerses Capital first reported a position in CMPX in Q2 2026 and held it in 1 quarter. The position peaked at $51.1K in Q2 2026. 172 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • nVerses Capital reported no remaining Compass Therapeutics position as of Q3 2026 after selling out during the quarter.
  • nVerses Capital sold 23,330 Compass Therapeutics shares in Q3 2026, an estimated $51.1K.
  • nVerses Capital first reported a position in Compass Therapeutics in Q2 2026 and held it in 1 quarter.
  • nVerses Capital's Compass Therapeutics position peaked at $51.1K in Q2 2026.
  • 172 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on nVerses Capital's 13F filing for Q3 2026.